A 7% decrease in sales in the U.S., Canada, and Latin America undermined financial results for SuperSonic Imagine in calendar year 2015.
The ultrasound technology developer increased sales by 1% overall to 21.7 million euros last year, compared with 21.5 million euros in 2014.
Supersonic Imagine also reported a net loss of 11.6 million euros in 2015, compared with a net loss of 9.5 million euros in 2014. The company blamed currency fluctuations and increased operating expenses for the larger net loss in 2015.
In other company news, Supersonic Imagine has entered into an agreement in which U.S. firm Sandhill Scientific will have rights to sell SuperSonic Imagine's Aixplorer ultrasound system to gastroenterologists and hepatologists. SuperSonic Imagine's direct sales force will continue to target radiology, breast, and other clinical segments in the U.S.